The company has reached supply agreements with governments around the world for a separate potential vaccineAstrazeneca has begun human trials of an antibody treatment that could be used to protect people from the coronavirus. The Cambridge-based FTSE 100 company said that the trial would involve up to 48 healthy participants in the UK, aged 18 to 55 years old. The antibody therapy could be an option where a vaccine is unsuitable, including for people whose natural defences are compromised by immunosuppressant drugs or chemotherapy. It could also be used to boost the immune systems of older people who are at a heightened risk. Astrazeneca said that the phase-one

Source: The Times August 25, 2020 08:03 UTC